Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Who's giving there shares away ?

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon May 10, 2021 11:01am

151 Views

Post# 33164777

RE:RE:Who's giving there shares away ?

Layth1990 wrote: We need series of good news to change the momentum. I can tell people just want to get out with slight increase in SP. This should change if management stick to its schedule.

True - I think it's probably in the works. Going to the NASDAQ in the fall will need some strong share price movement upwards. I think amalgamation was a necessary evil to get to that point.

For now, I'll take the shaking of the tree and dropping all the weak leaves. We just don't need them hanging around. They'd eventually exit on a quick upswing. Get rid of them now.

: )

<< Previous

Bullboard Posts

Next >>

A potential breakthrough in spinal cord and optic nerve injury treatment